Increased life expectancy resulting from addition of l-deprenyl to Madopar� treatment in Parkinson's disease: A longterm study

Birkmayer, W., Hornykiewicz, O.: Der L-Dioxyphenylalanin-Effect beim Parkinson-Syndrom des Menschen. Arch. Psychiat. Nervenkrh.203, 560?571 (1962).

Birkmayer, W., Knoll, J., Riederer, P., Youdim, M. B. H.: L-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. In: Monoamine Oxidase and its Selective Inhibitors (Beckmann, H., Riederer, P., eds.), pp. 170?177. Basle: Karger. 1983.

Birkmayer, W., Neumayer, E.: Die moderne medikamentöse Behandlung des Parkinsonismus. Z. Neurol.202, 257?280 (1972).

Birkmayer, W., Riederer, P., Youdim, M. B. H., Linauer, W.: Potentation of antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, l-deprenyl. J. Neural Transm.36, 303?323 (1975).

Burns, R. S., Chiueh, C. C., Markey, S. R., Ebert, M. H., Jacobowitz, D., Kopin, I. J.: A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by l-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U.S.A.80, 4546?4550 (1983).

Calne, D. B., Langston, J. W.: Aetiology of Parkinson's disease. Lancet2, 1457?1459 (1983).

Cohen, G.: The pathobiology of Parkinson's disease: Biochemical aspects of dopamine neurons senescence. J. Neural Transm., Suppl.19, 89?103 (1983).

Davis, G. C., Williams, A. C., Markey, S. P., Eberl, M. H., Caine, E. D., Reichert, C. M., Kopin, I.J.: Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat. Res.1, 249?254 (1979).

Diamond, S. G., Markham, C. H., Treciokas, L.J.: Long-term experience with L-dopa: Efficacy, progression and mortality. In: Advances in Parkinsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 444?455. Basle: Editiones Roche 1976.

Dixon, W.J., Brown, M. B.: Biomedical Computer Programs P-Series 1981, Univ. of California Press, Berkley, Ca., 1982.

Elsworth, J. D., Glover, V., Reynolds, G. P., Sandler, M., Lees, A. J., Phuapradit, P., Shaw, K. M., Stern, G. M., Kumar, P.: Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the cheese effect. Psychopharmacology57, 33?38 (1978).

Glover, V., Sandler, M., Owen, F., Riley, G.J.: Dopamine is a monoamine oxidase B substrate in man. Nature (London)265, 80?81 (1977).

Green, A. R., Mitchell, B. D., Tordoff, F. C., Youdim, M. B. H.: The evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brainin vivo and for degree of inhibition of enzyme necessary for increased functional activity of dopamine. Br. J. Pharmacol.60, 343?349 (1977).

Halliwell, B., Cutteridge, J. M. C.: Oxygen radicals and the nervous system. TINS Jan., 22?26 (1985).

Heikkila, R. E., Manzino, L., Cabbat, F. C., Duvoisin, R. C.: Protection against the dopaminergic neurotoxicity of l-methyi-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature (London)311, 467?469 (1984).

Hoehn, M. M., Yahr, M. D.: Parkinsonism; onset, progression and mortality. Neurology17, 427?442 (1967).

Johnston, J. P.: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol.17, 1285?1297 (1968).

Kalir, A., Sabbagh, A., Youdim, M. B. H.: Selective acetylenic suicide and reversible inhibitors of monoamine oxidase types A and B. Br. J. Pharmac.73, 55?64 (1981).

Knoll, J.: Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In: Ciba Foundation Symposium 39 (New Ser.) Monoamine Oxidase and its Inhibition, pp. 135?155. Amsterdam: Elsevier. 1972.

Knoll, J.: Monoamine oxidase chemistry and pharmacology. In: Enzyme Inhibitors as Drugs (Sandler, M., ed.), pp. 151?173. London: Macmillan. 1980.

Knoll, J., Magyar, K.: Some puzzling pharmacological effect of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol.5, 393?408 (1972).

Knoll, J., Eczery, Z., Kelemen, K., Nievel, J., Knoll, B.: Phenylisopropyl-methylpropinylamine (E-250), a new spectrum psychic energizer. Arch. Int. Pharmacodyn.155, 154?164 (1965).

Knoll, J., Vizi, E. S., Somogyi, E.: Phenylisopropyl-methylpropinylamine (E-250), a monoamine oxidase inhibitor antagonizing the effect of tyramine. Arzneim. Forsch/Drug Res.18, 109?112 (1968).

Langston, J. W., Ballard, P. A.: Parkinson's disease in a chemist working with l-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med.309, 310 (1983).

Langston, J. W., Ballard, P., Tetrud, J. W., Irwin, L: Chronic parkinsonism in human due to a product of meperidine-analog synthesis. Science219, 979?980 (1983).

Langston, J. W., Irwin, I., Langston, E.B.: Pargyline prevents MPTP-induced parldnsonism in primates. Science225, 1480?1482 (1984).

Lees, A. J., Kohout, L. J., Shaw, K. M., Stern, G. M., Elsworth J. D., Sandler, M., Youdim, M. B. H.: Deprenyl in Parkinson's disease. The Lancetii, 791?795 (1977).

Markey, S. P., Johanssen, J. N., Chiueh, C. C., Burns, R. S., Hekernham, M. A.: Intraneuronal generation of a pyndinmm metabolite may cause drug-induced parldnsonism. Nature311, 464?467 (1984).

Riederer, P., Jellinger, K., Seemann, D.: Monoamine oxidase and Parkinsonism. In: Monoamine Oxidase and Disease (Tipton, K. F., Dostert, P., Strolin-Benedetti, M., eds.), pp. 403?415. London: Academic Press. 1984.

Riederer, P., Youdim, M. B. H., Rausch, W. D., Birkmayer, W., Jellinger, K., Seemann, D.: On the mode of action of l-deprenyl in human central nervous system. J. Neural Transm.43, 217?226 (1978).

Rinne, U. K., (ed.): A new approach to the treatment of Parkinson's disease. Acta Neurol. Scand. (Suppl. 95)68, 7?144 (1983).

Squires, R. M.: Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability. Adv. Biochem. Psychopharmacol.5, 355?370 (1972).

Yahr, M. D.: Evaluation of long-term therapy in Parkinson's disease: Mortality and therapeutic efficacy. In: Advances in Parldnsonism (Birkmayer, W., Hornykiewicz, O., eds.), pp. 435?443. Basle: Editiones Roche 1976.

Yahr, M. D.: Overview of present day treatment of Parkinson's disease. J. Neural Transm.48, 227?238 (1978).

Youdim, M. B. H.: Oxidation of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by rat brain coupled to tetrazolium nitro blue. Eur. J. Pharmac. (1985) in press.

Youdim, M. B. H., Finberg, J. P. M.: Monoamine oxidase inhibitor antidepressants. In: Psychopharmacology 1/2 (Grahame-Smith, D. G., Hippius, H., Winokur, G., eds.), pp. 35?71. London: Excerpta Medica. 1985.

Youdim, M. B. H., Collins, C. G. S., Sandler, M.: Multiple forms of rat brain monoamine oxidase. Nature (London)223, 626?628 (1969).

Youdim, M. B. H., Collins, C. G. S., Sandler M.: Monoamine oxidase, multiple forms and selective inhibitors. Biochem. J.121, 134?136 (1971).

Youdim, M. B. H., Collins, C. G. S., Sandler, M., Bevan Jones, A. B., Pare, C. M. B., Nicholson, W.J.: Human brain monoamine oxidase: Multiple forms and selective inhibitors. Nature (London)236, 225?228 (1972).

Youdim, M. B. H., Finberg, J. P. M., Riederer, P., Heikkila, R. E.: Monoamine oxidase B inhibitors in human and animal parkinsonism. In: Basic and Therapeutic Strategies in Alzheimer's and Other Age Related Neuropsychiatric Disorders (Fisher, A., ed.). New York: Plenum Press 1985 (in press).